NextSharkNextShark.com

10-year-old girl becomes first in Taiwan to fully recover from leukemia via CAR T-cell therapy

10-year-old girl becomes first in Taiwan to fully recover from leukemia via CAR T-cell therapy

A 10-year-old girl with leukemia became the first in Taiwan to have been successfully treated with a new form of immunotherapy. 

July 15, 2022
SHARE
A 10-year-old girl with leukemia became the first in Taiwan to have been successfully treated with a new form of immunotherapy. 
The patient, identified only as Ting-ting (亭亭), underwent CD19 chimeric antigen receptor (CAR) T-cell therapy at the National Taiwan University Hospital (NTUH).
CAR T-cell therapy is an immunotherapy treatment that became prominent in 2012 after 6-year-old American girl Emily Whitehead was successfully treated for her leukemia in a clinical trial. 
During a news conference, Ting-ting’s doctors revealed that the patient initially received targeted chemotherapy after she was diagnosed with pediatric B-cell acute lymphoblastic leukemia at age 6. For a period of time, her remaining cancer cells were undetectable after receiving a three-year chemotherapy regimen for high-risk groups.
The doctors recommended using CAR T-cell therapy on Ting-ting after her leukemia recurred last year.
Subscribe to
NextShark's Newsletter

A daily dose of Asian America's essential stories, in under 5 minutes.

Get our collection of Asian America's most essential stories to your inbox daily for free.

Unsure? Check out our Newsletter Archive.

The therapy involves the extraction of immune cells called T-cells from a patient’s blood.
The cells are modified by adding a gene for a CAR before being injected back into the patient. The modification makes them attach to the specific cancer cell antigen.
In April, Ting-ting’s cancer went into complete remission soon after she was infused with CD19 CAR T-cells. According to the doctors, the patient even spent her 10th birthday with her family at home.
The patient’s mom lamented the difficulty in explaining the cancer diagnosis to her young child, which she eventually likened to “having a cold” that would go away after taking her medicine.
She then thanked the medical team for discussing the option of CAR T-cell therapy with her.
Ting-ting’s case shows that the CD19 CAR T-cell therapy has the potential to help other children in Taiwan, where, according to NTUH’s Department of Pediatrics Director Lee Wang-tso (李旺祚), cancer is the second-leading cause of death among children.
However, since the treatment is currently not covered by the National Health Insurance, Ting-ting’s parents were forced to sell their home to pay the cost amounting to NT$10 million (approximately $334,180).
The hospital said that the National Health Insurance Administration is reviewing whether to cover such treatments for future cases.
 
Featured Image via 三立iNEWS
MOST READ
    HAPPENING NOW
      Ryan General

      Ryan General is a Senior Reporter for NextShark

      SHARE THIS ARTICLE:

      RELATED STORIES FROM NEXTSHARK

      Support
      NextShark's
      Journalism

      Many people might not know this, but NextShark is a small media startup that runs on no outside funding or loans, and with no paywalls or subscription fees, we rely on help from our community and readers like you.

      Everything you see today is built by Asians, for Asians to help amplify our voices globally and support each other. However, we still face many difficulties in our industry because of our commitment to accessible and informational Asian news coverage.

      We hope you consider making a contribution to NextShark so we can continue to provide you quality journalism that informs, educates, and inspires the Asian community. Even a $1 contribution goes a long way. Thank you for supporting NextShark and our community.

      © 2023 NextShark, Inc. All rights reserved.